Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

Arno Therapeutics, Inc. ARNI, a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15th European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain. Logistical details for the poster presentation include: Poster PE6/4: AR-12, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro First Author: Stefan Proniuk, PhD Date, Time: Wednesday, October 21 at 3:00 p.m. CEST through Saturday, October 24 at 12:00 p.m. CEST Location: Exhibition Area, Level 0